---
title: "Methylation-Based ctDNA Surveillance Detects Recurrence in Non-Viral Head and Neck Cancer"
id: "medrxiv-5-methylation-based-ctdna-for-post-treatment-surveillance-of-non-viral-head-and"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-5-methylation-based-ctdna-for-post-treatment-surveillance-of-non-viral-head-and"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.17.26363361v1?rss=1"
published_at: "2026-09-20T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Methylation-Based ctDNA Surveillance Detects Recurrence in Non-Viral Head and Neck Cancer
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-5-methylation-based-ctdna-for-post-treatment-surveillance-of-non-viral-head-and
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.17.26363361v1?rss=1)
- **Published At:** 2026-09-20T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This single-institution retrospective cohort evaluated a **methylation-based ctDNA** assay (Guardant360) for post-treatment surveillance of non-virally associated head and neck squamous cell carcinoma (HNSCC). - Fifty patients with non-metastatic, non-viral HNSCC underwent definitive therapy and had at least one post-treatment plasma ctDNA test between January 2024 and October 2025. - Guardant360 identifies tumor-specific **DNA methylation** patterns in plasma cell-free DNA; a positive result was defined as methylation signal ≥0.05%. - At median 18.0 months follow-up, 13 patients recurred; 12 had positive ctDNA results. The assay demonstrated sensitivity 76.9%, specificity 94.6%, PPV 83.3%, NPV 92.1%, and AUC 0.858 (95% CI, 0.733–0.982). - Positive post-treatment **ctDNA** correlated with markedly worse progression-free survival (1-year PFS 25.0% vs 96.4%) and overall survival (1-year OS 75.0% vs 100%); P < .001 for both comparisons. - In 10 patients with recurrence and positive ctDNA, ctDNA preceded clinical detection in 6 (60%) by a median of 131 days. - Exploratory mutation analysis identified associations between recurrence and mutations in **TP53**, **SETD2**, and **ROBO2**. - Authors conclude the methylation-based ctDNA assay showed high diagnostic performance and prognostic value in non-viral HNSCC surveillance but note that prospective validation is required. - The study is a preprint (not peer reviewed); ethical approval was provided by the Albert Einstein College of Medicine IRB, and de-identified data are available on request.
## Clinical Analysis & Structured Key Points
Methylation-Based ctDNA for Post-Treatment Surveillance of Non-Viral Head and Neck Cancer | medRxiv Skip to main content Methylation-Based ctDNA for Post-Treatment Surveillance of Non-Viral Head and Neck Cancer Danielle Tomer , Patrik Brodin , Nikhil Malik , Sadiya Mayat , Christian Velten , Byung-Han Rhieu , Enrico Castellucci , Bradley Schiff , Vikas Mehta , Richard Smith , Shalom Kalnicki , Madhur Garg , Rafi Kabarriti doi: https://doi.org/10.64898/2026.09.17.26363361 Danielle Tomer 1 Albert Einstein College of Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Patrik Brodin 2 Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Nikhil Malik 2 Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Sadiya Mayat 2 Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Christian Velten 2 Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Byung-Han Rhieu 2 Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Enrico Castellucci 3 Department of Medical Oncology, Montefiore Einstein Comprehensive Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Bradley Schiff 4 Department of Otorhinolaryngology - Head & Neck Surgery, Montefiore Einstein Comprehensive Cancer Center Find this author on Google Scholar Find this author on PubMed Search for this author on this site Vikas Mehta 4 Department of Otorhinolaryngology - Head & Neck Surgery, Montefiore Einstein Comprehensive Cancer Center Find this author on Google Scholar Find this author on PubMed Search for this author on this site Richard Smith 4 Department of Otorhinolaryngology - Head & Neck Surgery, Montefiore Einstein Comprehensive Cancer Center Find this author on Google Scholar Find this author on PubMed Search for this author on this site Shalom Kalnicki 2 Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Madhur Garg 2 Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Rafi Kabarriti 2 Department of Radiation Oncology, Montefiore Einstein Comprehensive Cancer Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: rkabarri{at}montefiore.org Abstract Info/History Metrics Data/Code Preview PDF Abstract Importance: Recurrence rates in head and neck squamous cell carcinoma (HNSCC) remain high, yet current post-treatment surveillance relies primarily on clinical examination and imaging with known limitations. Circulating tumor DNA (ctDNA) has shown promise for recurrence detection in HPV-positive HNSCC, but less is known about its role in non-virally associated disease. Objective: To evaluate the diagnostic performance of a methylation-based ctDNA assay for detecting recurrence during post-treatment surveillance of non-virally associated HNSCC and to assess its prognostic association with survival outcomes. Design, Setting, and Participants: This retrospective single-institution cohort study included patients with non-metastatic non-virally associated HNSCC who underwent definitive therapy and had at least one Guardant360 ctDNA test during post-treatment surveillance between January 2024 and October 2025. Guardant360 identifies tumor-specific DNA methylation patterns via next-generation sequencing of plasma cell-free DNA. A positive result was defined by a methylation signal of 0.05% or greater. Main Outcomes and Measures: Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the receiver operating characteristic curve (AUC). Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. Results: Fifty patients were included; most had larynx (38%) or oral cavity (36%) primaries, AJCC stage IVA-IVB disease (72%), T3-T4 tumors (69%), and N2-N3 nodal classification (48%). Treatment was chemoradiation (54%) or surgery (46%). At a median follow-up of 18.0 months, 13 patients recurred, and 12 had positive ctDNA results. Sensitivity, specificity, PPV, and NPV were 76.9%, 94.6%, 83.3%, and 92.1%, respectively (AUC, .858; 95% CI, .733-.982). Positive ctDNA was associated with worse PFS (1-year: 25.0% vs 96.4%; P < .001) and OS (1-year: 75.0% vs 100%; P < .001). Among 10 patients with recurrence and positive ctDNA, ctDNA preceded clinical detection in 6 (60%) by a median of 131 days. An exploratory analysis identified TP53, SETD2, and ROBO2 mutations as associated with recurrence. Conclusions and Relevance: A methylation-based ctDNA assay demonstrated high sensitivity and specificity for detecting disease recurrence in non-virally associated HNSCC. Positive post-treatment ctDNA was associated with inferior survival and preceded clinical detection in most cases, supporting ctDNA integration into surveillance strategies, though prospective validation is warranted. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The IRB of Albert Einstein College of Medicine gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The de-identified data that support the findings of this study are available from the corresponding author upon reasonable request. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted September 20, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Methylation-Based ctDNA for Post-Treatment Surveillance of Non-Viral Head and Neck Cancer Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Methylation-Based ctDNA for Post-Treatment Surveillance of Non-Viral Head and Neck Cancer Danielle Tomer , Patrik Brodin , Nikhil Malik , Sadiya Mayat , Christian Velten , Byung-Han Rhieu , Enrico Castellucci , Bradley Schiff , Vikas Mehta , Richard Smith , Shalom Kalnicki , Madhur Garg , Rafi Kabarriti medRxiv 2026.09.17.26363361; doi: https://doi.org/10.64898/2026.09.17.26363361 Share This Article: Copy Citation Tools Methylation-Based ctDNA for Post-Treatment Surveillance of Non-Viral Head and Neck Cancer Danielle Tomer , Patrik Brodin , Nikhil Malik , Sadiya Mayat , Christian Velten , Byung-Han Rhieu , Enrico Castellucci , Bradley Schiff , Vikas Mehta , Richard Smith , Shalom Kalnicki , Madhur Garg , Rafi Kabarriti medRxiv 2026.09.17.26363361; doi: https://doi.org/10.64898/2026.09.17.26363361 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Oncology Subject Areas All Articles Addiction Medicine (619) Allergy and Immunology (903) Anesthesia (334) Cardiovascular Medicine (4829) Dentistry and Oral Medicine (479) Dermatology (419) Emergency Medicine (651) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1633) Epidemiology (15975) Forensic Medicine (33) Gastroenterology (1206) Genetic and Genomic Medicine (7067) Geriatric Medicine (734) Health Economics (1067) Health Informatics (5060) Health Policy (1438) Health Systems and Quality Improvement (1775) Hematology (587) HIV/AIDS (1347) Infectious Diseases (except HIV/AIDS) (16307) Intensive Care and Critical Care Medicine (1174) Medical Education (671) Medical Ethics (155) Nephrology (727) Neurology (7292) Nursing (368) Nutrition (1084) Obstetrics and Gynecology (1244) Occupational and Environmental Health (1005) Oncology (3615) Ophthalmology (1055) Orthopedics (398) Otolaryngology (457) Pain Medicine (473) Palliative Medicine (139) Pathology (709) Pediatrics (1805) Pharmacology and Therapeutics (739) Primary Care Research (768) Psychiatry and Clinical Psychology (5920) Public and Global Health (9770) Radiology and Imaging (2433) Rehabilitation Medicine and Physical Therapy (1456) Respiratory Medicine (1250) Rheumatology (643) Sexual and Reproductive Health (773) Sports Medicine (581) Surgery (782) Toxicology (107) Transplantation (305) Urology (293)
## Related Clinical Research

- [Inflammatory Biomarkers and Risk of Postmenopausal ER-Positive Breast Cancer](https://medichelpline.com/clinical-feed/british-journal-of-cancer-0-inflammatory-biomarkers-and-risk-of-postmenopausal-oestrogen-receptor-positive.md)
- [Sudan civil war damages hospitals, forcing cancer patients into dangerous journeys](https://medichelpline.com/clinical-feed/stat-news-2-in-sudan-attacks-on-hospitals-force-patients-to-make-dangerous-journeys.md)
- [Educating Patients on ‘Asian Glow’ and Alcohol Risks in East Asian Populations](https://medichelpline.com/clinical-feed/stat-news-0-opinion-doctors-should-educate-patients-about-asian-glow-and-drinking-risks.md)
- [Autologous DC-CIK Cell Therapy Combined with Multidisciplinary Care in Advanced Pancreatic Cancer:](https://medichelpline.com/clinical-feed/frontiers-in-immunology-17-multidisciplinary-treatment-incorporating-autologous-dc-cik-cell-therapy.md)
- [Federated Learning and In-House Dashboards for Data Quality Assurance in Multi‑Center Oncology Data](https://medichelpline.com/clinical-feed/medrxiv-14-data-auditing-and-quality-assurance-in-a-federated-learning-consortium-getting.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.